This news helped Aarti Drugs to surge 11 per cent on August 17
This news helped Aarti Drugs to surge 11 per cent on August 17

This news helped Aarti Drugs to surge 11 per cent on August 17

Aarti Drugs Ltd is involved in the manufacturing and selling of Active Pharmaceutical Ingredients, Pharma Intermediates, Specialty Chemicals, and Formulations.

DSIJ Intelligence Article rating: 5.0

The shares of Aarti Drugs are rallying due to news regarding imposing anti-dumping duty on Chinese pharma companies to sell Ofloxacin and other intermediates in the Indian market.  

Closing Bell: Markets end lower; realty and public sector enterprises drag, FMCG and pharma shine!
Closing Bell: Markets end lower; realty and public sector enterprises drag, FMCG and pharma shine!

Closing Bell: Markets end lower; realty and public sector enterprises drag, FMCG and pharma shine!

On Wednesday, the headline equity indices, Sensex and Nifty ended slightly lower after a positive opening in the morning session of the trade.  

DSIJ Intelligence Article rating: 4.5

On Wednesday, the headline equity indices, Sensex and Nifty ended slightly lower after a positive opening in the morning session of the trade.  

Closing bell: Markets tank amidst weak global cues; banks, metals, and pharma stocks suffer!
Closing bell: Markets tank amidst weak global cues; banks, metals, and pharma stocks suffer!

Closing bell: Markets tank amidst weak global cues; banks, metals, and pharma stocks suffer!

HDFC Bank, Reliance Industries, Bajaj Finance, Tata Steel, and TCS rallied heavily whereas a large volume was traded in Coal India, Hindalco Industries, Adani Ports, SBI, & ITC.

DSIJ Intelligence Article rating: 4.3

At market close today, the core equity indices i.e. Sensex and Nifty 50 were down by 1.25 per cent each. Weaker global cues, the aggressive rate hike confirmation from FED Chairman, and rising bond yield in the US coupled with a volatile rally in technology sector stocks have led to the bloodbath on the bourses yet again.  

RSS
12

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR